Par Drugs and Chemicals Q4 FY26 Results: Announced May 14 2026 Pharmaceuticals and Chemicals

May 15, 2026
Posted by: Kunal Singla
Category: News

Par Drugs and Chemicals Q4 FY26 results were announced on May 14, 2026, at the company’s board meeting. Q4 FY26 PAT approximately Rs 2 crore on revenue approximately Rs 30 crore. Pharmaceutical and chemical manufacturer. Results filed with BSE on May 14, 2026. Investors tracking the company will find complete financial data, analysis, and FY27 outlook in this article.

Click Here – Get Free Investment Predictions

Table of Contents

Par Drugs and Chemicals Q4 FY26 Key Financial Highlights

Metric	Q4 FY26	Comparison
PAT (Net Profit)	Rs 2 crore	Q4 FY26
Revenue from Operations	Rs 30 crore	Q4 FY26
Ticker	PARDRUG	Sector: Pharmaceuticals and Chemicals

Screen the best stocks on the Univest Screener.

Par Drugs and Chemicals Performance Analysis

The company results reflect the company’s operational performance during the January to March 2026 quarter. the company results announced May 14, 2026. The company manufactures pharmaceutical formulations and specialty chemicals for domestic and export markets. Investors and analysts monitoring the company results will focus on FY27 revenue guidance, margin trajectory, and management commentary on business outlook.

The company performance positions the company for FY27. Track the company analyst ratings and live stock price on the Univest Screener for real-time investment insights.

Par Drugs and Chemicals FY27 Outlook

Post Par Drugs and Chemicals, investor focus for FY27 will be on revenue growth momentum, margin expansion, new order wins, and sector-specific tailwinds in the Pharmaceuticals and Chemicals space. The Par Drugs and Chemicals results demonstrate the company’s execution capabilities. Track Par Drugs and Chemicals updates on the Univest Screener for analyst views and FY27 earnings estimates.

Download the Univest iOS App or the Univest Android App to track live price and Q4 FY26 earnings updates.

Frequently Asked Questions on Par Drugs and Chemicals Q4 FY26 Results

What is Par Drugs and Chemicals Q4 FY26 PAT?

Ans. Par Drugs and Chemicals Q4 FY26 PAT of Rs 2 crore (results declared May 14, 2026). Q4 FY26 PAT approximately Rs 2 crore on revenue approximately Rs 30 crore. Pharmaceutical and chemical manufacturer. Results filed with BSE on May 14,.

When did Par Drugs and Chemicals announce Q4 FY26 results?

Ans. the company results were announced on May 14, 2026, at the company’s board meeting and filed with BSE and NSE.

What is the FY27 outlook for Par Drugs and Chemicals?

Ans. Post the company results, investors will track FY27 guidance and growth strategies in the Pharmaceuticals and Chemicals sector. Track live updates on the Univest Screener.

Where can I track Par Drugs and Chemicals Q4 FY26 live data?

Ans. Track the company live stock price, analyst ratings, and earnings updates on the Univest Screener for real-time investment data.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered advisor before making any investment decision.

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.